11.27.24 -- Find The Perfect CDMO Partner For Your Project

Our injectables CDMO expertise can support your molecule, with a team skilled in complex formulations, over 20 commercial products, a 40+ year regulatory history, and a new isolator filler capacity.

Review our high-quality GMP manufacturing capabilities, featuring an isolator-based filling platform and fill-finish capacity for vials, syringes, and cartridges, and recent facility expansion.

Jeff Clement, Executive Director of Technical Sales Drug Product Development and Manufacturing, outlines our global sterile fill-finish and lyophilization capabilities, investments, and expansions.

Explore our exceptional injectable manufacturing capabilities, featuring our high-speed, multi-purpose fill-finish line for vials, syringes, and cartridges at our San Diego facility.

Enhance your injectable projects with our expertise and expanded capacity to meet the demand for vials, pre-filled syringes, and cartridges from pre-clinical development to commercial launch.

Partner with us to access the critical services that drive your success — supporting everything from technical and development batches to Phase 1 clinical trials and product launch.

Learn about our new facility expansions, enhanced filling capacity, and advanced packaging capabilities that are designed to support and elevate your drug development projects.

Our full-service model enables us to collaborate with partners on sterile injectable projects, delivering quality products for both early clinical stages and large-scale commercial supply.

Let us support your high-quality medicines with integrated offerings in mammalian drug substances and drug products, including our fill and finish services for vials, syringes, cartridges, and auto-injectors.

Alcami provides sterile drug product fill-finish services, including formulation development, complex formulations, clinical manufacturing, batch scale-up, and commercial production.

Witness how our 80 years of industry experience and a global capacity of ~1,000 m³ can provide scalable, high-quality solutions to support your small molecule programs.

Use our services and solutions to advance small molecule development — from initial design and optimization to full-scale manufacturing and comprehensive analytical support.

Advance your pharmaceuticals and biologics from development to delivery with our services in oral solid dose development, clinical manufacturing, and commercial packaging solutions.

See how our AI-enabled Route Scouting Service simplifies the complexity of small molecule APIs, optimizing synthetic routes and accelerating clinical readiness.

Watch this overview of our extensive capabilities, including a deep dive into our HPAPI and API services and the available capacity at our Campoverdi, Italy facility for your next project.

With advanced infrastructure and a comprehensive approach, see why we're well-positioned to support the development of stable, effective, and safe injectable products for advanced therapeutics.

Discover how our recent investments have expanded our capacity for developing, manufacturing, and packaging highly potent drug products, leveraging over 35 years of expertise.

Streamline your ADC project with the Proveo™ alliance, offering seamless, end-to-end support across antibody production, bioconjugation, and aseptic fill.

Utilize our integrated CRO and CDMO services for developing and manufacturing complex biologics, bioconjugates, and ADCs, ensuring high-quality products and data packages.

This presentation underscores the essential role of comprehensive characterization in ensuring that ADCs not only meet regulatory standards but also achieve therapeutic goals.

Partner with us for full-service ADC development and production, from feasibility to GMP manufacturing, with industry-leading standards and flexible capacities.

Leverage our flexible solutions and access to proprietary CHO-K1 cell lines in our state-of-the-art cGMP suites equipped with both single-use and traditional stainless steel bioreactors.

We've expanded our U.S. and Germany sites to offer end-to-end services for product development, clinical and commercial fill/finish, and ADC conjugation and purification by 2025.

Advance ADC development with the SMARTag® Platform, combining precision bioconjugation and a linker-payload library to enhance the therapeutic index and accelerate timelines.